Summit Securities Group’s Starling Oncology STLN Stock Holding History

Summit Securities Group’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12.6K	Buy	+1,992	New	+$11.9K	﹤0.01%	774

Other funds holding STLN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Mount Lucas Management Newtown, Pennsylvania $333M AUM 24.96% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return

Summit Securities Group's STLN Position: Q3 2026 in Review

Summit Securities Group opened a new position in Starling Oncology (STLN) in Q3 2026: 1,992 shares worth $12.6K. The stake represents ﹤0.01% of the portfolio and ranks #774 among its holdings.

55 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

Summit Securities Group held 1,992 shares of Starling Oncology worth $12.6K as of Q3 2026.
Starling Oncology was a new Summit Securities Group position in Q3 2026.
Starling Oncology made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #774 holding.
55 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.